Skip to content
DataLookout
Menu

DynaMMic-1NCT05714839

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 60 words
    • Trial sites expanded: 44 → 59 locations
  2. Notable Primary endpoint(s) modifiedv9 Show 4 more changesShow less
    • Eligibility criteria expanded, about 172 words
    • Trial sites expanded: 36 → 44 locations
    • Interventions: Belantamab mafodotin (Drug), Unconjugated belantamab antibody (Drug), Unconjugated belantamab antibody and belantamab mafodotin (Drug)… to Belantamab (Drug), Belantamab mafodotin (Drug), Dexamethasone (Drug), Pomalidomide (Drug)
    • Secondary endpoints revised (26)
  3. Notable Primary and study completion moved earlier from Dec 3, 2029 to Aug 3, 2028v8 Show 6 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 74 words
    • Enrollment reduced: 152 → 123 participants
    • Trial sites expanded: 30 → 36 locations
    • Interventions: Belantamab mafodotin (Drug), Unconjugated belantamab antibody (Drug), Unconjugated belantamab antibody and belantamab mafodotin (Drug)… to Belantamab mafodotin (Drug), Unconjugated belantamab antibody (Drug), Unconjugated belantamab antibody and belantamab mafodotin (Drug)…
    • Secondary endpoints: 31 to 26
  4. Minor Trial sites expanded: 27 → 30 locations
    • Enrollment target: 153 to 152
    v7
  5. Notable Phase: Phase 1 to Phase 1/2v6 Show 7 more changesShow less
    • Enrollment target: 55 to 153
    • Eligibility criteria expanded, about 608 words
    • Primary endpoints: 5 to 6
    • Study sites: 21 to 27
    • Interventions: Belantamab (Drug), Belantamab and belantamab mafodotin (Drug), Belantamab mafodotin (Drug) to Belantamab mafodotin (Drug), Unconjugated belantamab antibody (Drug), Unconjugated belantamab antibody and belantamab mafodotin (Drug)…
    • Secondary endpoints: 18 to 31
    • Study arms: 3 to 4
Show 4 earlier versionsHide 4 earlier versions
  1. Minor Enrollment target: 48 to 55
    • Study sites: 15 to 21
    v5
  2. Notable Primary and study completion dates: Sep 19, 2028 to Dec 3, 2029v4 Show 4 more changesShow less
    • Eligibility criteria expanded, about 42 words
    • Primary endpoints revised (5)
    • Study sites: 20 to 15
    • Start date: May 31, 2023 to Jun 14, 2023
  3. Notable Enrollment target: 124 to 48v3 Show 7 more changesShow less
    • Primary and study completion dates pushed to Sep 19, 2028
    • Eligibility criteria expanded, about 503 words
    • Primary endpoints: 4 to 5
    • Study sites: 17 to 20
    • Start date: Jun 14, 2023 to May 31, 2023
    • Interventions: Bela (Drug), Belamaf (Drug), Dexamethasone (Drug), Lenalidomide (Drug), Standard of Care (Drug) to Belantamab (Drug), Belantamab and belantamab mafodotin (Drug), Belantamab mafodotin (Drug)
    • Secondary endpoints: 12 to 18
  4. Notable Phase: Phase 1/2 to Phase 1v2 Show 5 more changesShow less
    • Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 28, 2023 to Jun 14, 2023
    • Study sites: 0 to 17
    • Primary completion date: Jun 28, 2027 to Sep 29, 2027
    • Study completion date: Jun 28, 2027 to Feb 29, 2028
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Parts 1, 2 and 3: Number of Participants with any Adverse Event
Timeframe: Up to 52 months
Part 1 (Dose escalation cohort) and Part 2: Number of Participants with Dose Limiting Toxicities (DLTs)
Timeframe: Cycle 1 (Each cycle is of 28 days)
Part 1, 2 and 3: Number of Participants with Worst Case Grade Change from Baseline in Laboratory and Vital Sign Parameters
Timeframe: Up to 52 months
Part 2: Number of Participants with severity of ocular events by the Keratopathy Visual Acuity (KVA) scale
Timeframe: Up to 52 months
Part 2: Overall Response Rate (ORR)
Timeframe: Up to 52 months
Part 3: Very Good Partial Response and better rate (VGPR+)
Timeframe: Up to 52 months

Secondary (26)

Part 1: Overall Response Rate (ORR)
Part 1: Observed Plasma Concentration of belantamab
Part 1: Area Under the Curve (AUC) of belantamab
Part 1: Maximum Concentration (Cmax) of belantamab
Part 1: Number of Participants with Anti-Drug Antibodies (ADA) against belantamab
Show 21 moreShow less
Part 1: Titers of ADA against belantamab
Part 2: Duration of Response (DoR)
Part 2: Observed Plasma Concentration of Total belantamab
Part 2: Area Under the Curve (AUC) of Total belantamab
Part 2: Maximum Concentration (Cmax) of Total belantamab
Part 2: Observed Plasma Concentration of belantamab mafodotin (ADC)
Part 2: Area Under the Curve (AUC) of belantamab mafodotin (ADC)
Part 2: Maximum Concentration (Cmax) of belantamab mafodotin (ADC)
Part 2: Observed Plasma Concentration of Cys-Monomethyl Auristatin-F (Cys-mcMMAF)
Part 2: Area Under the Curve (AUC) of Cys-mcMMAF
Part 2: Maximum Concentration (Cmax) of Cys-mcMMAF
Part 2: Number of Participants with ADAs against belantamab and belantamab mafodotin
Part 2: Titers of ADAs against belantamab and belantamab mafodotin
Part 3: Minimal residual disease (MRD) negativity rate in participants achieving at least VGPR
Part 3: Overall Response Rate (ORR)
Part 3: Duration Of Response (DoR)
Part 3: Observed Plasma Concentration of Total belantamab
Part 3: Area Under the Curve (AUC) of Total belantamab
Part 3: Maximum Concentration (Cmax) of Total belantamab
Part 3: Number of Participants with ADAs against belantamab
Part 3: Titers of ADAs against belantamab

Arms and interventions

Part 1: Dose escalation and expansion of belantamab monotherapyExperimental

Belantamab will be administered in participants with RRMM until progressive disease (PD)

Part 2: Belantamab and belantamab mafodotin (delivered as separate drugs) dose range findingExperimental

Participants with RRMM will receive belantamab and belantamab mafodotin

Part 3: Belantamab +pomalidomide/dexamethasone in 2L+ RRMMExperimental

Participants with RRMM will receive belantamab in combination with pomalidomide-dexamethasone backbone.

Part 1b: Optional belantamab mafodotinExperimental

Participants enrolled in Part 1 and Part 2 will be dosed until PD after which they will have the option to receive treatment with single agent belantamab mafodotin.

Drugs: Belantamab, Belantamab mafodotin, Pomalidomide, Dexamethasone

Sites

59 sites in 15 countries

United States 12, Japan 7, Argentina 6, Israel 6, Finland 4, Turkey (Türkiye) 4, Brazil 3, Taiwan 3, United Kingdom 3, Australia 2, China 2, Poland 2, South Africa 2, South Korea 2, Germany 1